QAX-028
- Generic Name
- QAX-028
Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT01068613
- Locations
- 🇺🇸
Spartanburg Medical Research, 485 Simuel Road, Spartanburg, South Carolina, United States
🇺🇸Advanced Clinical Research Institute, 1211 W. La Palma Ave, Anaheim, California, United States
🇺🇸New Orleans Center for Clinical Research - Knoxville, 1928 Alcoa Highway, Knoxville, Tennessee, United States
Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 29
- Registration Number
- NCT00568503
- Locations
- 🇩🇰
Novartis Investigator Site, Birkeroed, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath